Patients with Acute Respiratory Failure May Now Enroll in NIH-Sponsored Trial

Thursday, April 22, 2021 Clinical Trial of Therapeutics for Severely Ill Hospitalized COVID-19 Patients Begins A new clinical trial to test therapeutics in severely ill COVID-19 patients has begun enrolling participants. ACTIV-3 Critical Care is a master protocol designed to test multiple therapeutics at once. It will begin by testing Zyesami, an formulation of a synthetic vasoactive intestinal peptide which may have anti-inflammatory properties, and the antiviral remdesivir (Veklury). This placebo-controlled trial may reveal new treatment regimens for Acute Respiratory Distress Syndrome (ARDS), a life-threatening condition associated with SARS-CoV-2 infection. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107